Adults 18 to 35, any sex, with Plaque Induced Gingivitis. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Change From Baseline Gingivitis at Day 14 as Measured by Non-invasive Microimaging and Gingival Index.Primary· Baseline to Day 14
The predictive validity of a non-invasive microimaging technique for assessing experimental gingivitis (plaque induced), as compared with gingival index is not reported. The microimaging technique was used to measure changes in the gingival thickness of the inter-dental tooth area. This area measured did not represent the clinical status of the tissue surrounding the tooth.
The gingival index is reported. Loe and Silness Gingival Index (GI); scale: 0 = normal gingiva, 1 = mild inflammation, 2 = moderate inflammation, 3 = severe inflammation
Group
Value
95% CI
Plaque Induced Gingivitis
0.6
± 1.2
Oral Hygiene Maintenance
0.15
± 0.3
Change From Day 14 Gingivitis at Day 28 as Measured by Non-invasive Microimaging and Gingival Index.Primary· Day 14 to Day 28
The predictive validity of a non-invasive microimaging technique for assessing experimental gingivitis (plaque induced), as compared with gingival index is not reported. The microimaging technique was used to measure changes in the gingival thickness of the inter-dental tooth area. This area measured did not represent the clinical status of the tissue surrounding the tooth.
The gingival index is reported. Loe and Silness Gingival Index (GI); scale: 0 = normal gingiva, 1 = mild inflammation, 2 = moderate inflammation, 3 = severe inflammation
Group
Value
95% CI
Plaque Induced Gingivitis
0.08
± 0.4
Oral Hygiene Maintenance
0.08
± 0.2
Change From Baseline Gingivitis at Day 14 as Measured by Non-invasive Microimaging and Plaque Index.Secondary· Baseline to Day 14
The predictive validity of a microimaging technique for assessing experimental gingivitis, as compared with plaque index is not reported. The microimaging technique was used to measure changes in the gingival thickness of the inter-dental tooth area. This area measured did not represent the clinical status of the tissue surrounding the tooth.
The plaque index is reported. Visible Plaque Index; scoring: 0 = no plaque; 1 = visible plaque
Group
Value
95% CI
Plaque Induced Gingivitis
0.84
± 1.4
Oral Hygiene Maintenance
0.17
± 0.24
Change From Day 14 Gingivitis at Day 28 as Measured by Non-invasive Microimaging and Plaque Index.Secondary· Day 14 to Day 28
The predictive validity of a microimaging technique for assessing experimental gingivitis, as compared with plaque index is not reported. The microimaging technique was used to measure changes in the gingival thickness of the inter-dental tooth area. This area measured did not represent the clinical status of the tissue surrounding the tooth.
The plaque index is reported. Visible Plaque Index; scoring: 0 = no plaque; 1 = visible plaque
Group
Value
95% CI
Plaque Induced Gingivitis
0.11
± 0.18
Oral Hygiene Maintenance
0.105
± 0.5
Change From Baseline Angiogenesis Chemokine Concentration at Day 28Secondary· Baseline to Day 28
Assessment of the concentration of the angiogenesis chemokine angiopoietin-1 during experimental gingivitis.
Group
Value
95% CI
Plaque Induced Gingivitis
137825.56
± 339893.64
Oral Hygiene Maintenance
164411.80
± 408590.49
Adverse events — posted to ClinicalTrials.gov
Time frame: 6 weeks.
Reporting threshold: 5%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
Using an experimental, non-invasive intra-oral imaging device, this study evaluates the effects on the gingival tissue when oral hygiene is stopped in a section of the mouth for two weeks and gingivitis develops. The effects on the gingival tissue continues to be evaluated as oral hygiene is resumed and the gingival tissue returns to health.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
Other recruiting trials for Plaque Induced Gingivitis
Currently open trials in the same condition.
NCT06900881 — Role of Kefir Mouth Wash in Oral Health Status Amelioration
· Phase 2, PHASE3
· recruiting
NCT06352645 — Evaluation of Safety and Efficacy of Bixdo Ultra Compact Water Flosser
· NA
· recruiting
Other University of Washington trials
Trials by the same sponsor.
NCT07430852 — Inherited and Environmental Risks Acting on Body Weight
· NA
· not yet recruiting
NCT07466498 — Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate Canc
· Phase 2
· not yet recruiting
NCT06422299 — Developing and Testing an Online Intervention for Alcohol and Cannabis Misuse and Healthy Relationship Skills Among Youn
· NA
· not yet recruiting
NCT07322341 — SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer
· Phase 2
· not yet recruiting
NCT07332351 — Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle
· Phase 2
· not yet recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Washington
Last refreshed: 9 March 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03750955.